IFF Pharma Solutions to Showcase Plant-Based Dietary Supplement Ingredients and Technical Expertise at Vitafoods™ Europe 2025
Improving the World of Dietary Supplements with a Breadth of Proven Brands.
IFF (NYSE: IFF) Pharma Solutions is excited to announce its participation at Vitafoods™ Europe 2025, the premier global nutraceutical event. The team will showcase its cutting-edge dietary supplement plant-based ingredients portfolio of innovative and trusted brands including SeaGel®, VERDIGEL™ SC, GRINDSTED® Pectin Premium, Ac-Di-Sol®, Avicel®, Accelerate®, and METHOCEL™ in hall 4 at booth 4F25, May 20-22, at the Fira Barcelona Gran Via.
"We are excited to highlight vivid examples of how our high-quality functional ingredients and technical expertise help our customers produce superior supplements," said Firat Nalbantoglu, EMEA commercial leader, IFF Pharma Solutions. "Our technical and commercial experts look forward to offering solutions for formulation and processing challenges. If you aim to enhance efficacy and bioavailability in your dietary supplements, we invite you to discover new possibilities with us."
IFF Pharma Solutions is committed to advancing the dietary supplement industry with its portfolio of high-performance ingredients, offering plant-based solutions and vegan alternatives, as well as reliable technologies for immediate and controlled release:
- SeaGel® and VERDIGEL™ SC: These plant-based alternatives to gelatin offer clean-label, non-GMO solutions for superior quality and high performance vegan softgels.
- GRINDSTED® Pectin Premium: A renowned, citrus-sourced ingredient for plant-based gummies that delivers an excellent consumer experience.
- Avicel®: A cellulose-based tablet binder and filler, Avicel® ensures the production of small, high-quality tablets with low-dusting and efficient tableting processes. Avicel® acts as a suspending agent, enhancing the stability and efficacy of liquid formulations.
- Ac-Di-Sol®: A non-GMO cellulose-based tablet disintegrant that delivers nutritional ingredients faster.
- METHOCEL™: A versatile cellulose-based solution for vegetarian hard capsules and controlled-release tablet matrices – resistant to heat and humidity conditions.
- Accelerate®: A cellulose-based super disintegrant for immediate release.
Visit here to learn more about IFF Pharma Solutions.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421594635/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veracode Advances Application Risk Management with Innovations for Comprehensive Risk Visibility and Software Supply Chain Security22.4.2025 13:50:00 CEST | Press release
Strategic Enhancements to Veracode Risk Manager and Package Firewall Deliver Unified Security and Risk Prioritization Veracode, a global leader in application risk management, today unveiled new capabilities offering proactive risk mitigation and automated security at enterprise scale. With software supply chain attacks and open-source vulnerabilities at an all-time high, enhanced Veracode Risk Manager (VRM) and an early access program for Veracode Package Firewall come at a critical juncture. The innovations represent a significant milestone in Veracode’s vision to deliver centralized risk visibility and secure development from the start. “Security teams face immense pressure to combat evolving threats, while developers require the flexibility to innovate quickly,” said Derek Maki, Head of Product at Veracode. “Our latest Application Risk Management platform enhancements provide organizations with the tools to not just identify risks, but to trace them to their root cause and prevent
Antibody Solutions Launches Single Plasma B-Cell Services through Cellestive Discovery Platform22.4.2025 13:00:00 CEST | Press release
New, exclusive capability will allow antibody discovery clients to access more hits and more screening data than competing technologies Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells. The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making. “This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, Phd, co-founder and president o
Sun Nuclear Announces Completion of Transition to CE Class IIb EU MDR Certification for Key Quality Management Solutions22.4.2025 12:04:00 CEST | Press release
SunCHECK® Software, SRS MapCHECK® and SunSCAN™ 3D DevicesAmong 15+ Solutions Awarded New Certification Sun Nuclear, a Mirion Medical company, announced today that its SunCHECK® Quality Management software and key radiation therapy Quality Assurance (QA) devices have been awarded CE Class IIb certification under the European Medical Devices Regulation 2017/745 (EU MDR). The transition to EU MDR Class IIb recognizes the safety and performance of Sun Nuclear solutions and confirms compliance with stringent safety requirements. Sun Nuclear solutions awarded Class IIb certification include: The SunCHECK® Platform, a comprehensive software application facilitating essential Patient and Machine QA workflows and centralized data management; Patient-specific QA solutions, including the ArcCHECK®, ArcCHECK®-MR, MapCHECK® 3 and SRS MapCHECK® devices, for measurement of radiation dose distributions against planned doses; Machine QA solutions, including the Daily QA™ 3, Daily QA™ 3-MR, IC PROFILER™
Regula Becomes the First to Verify All Dynamic Security Features in Remote Document Checks22.4.2025 12:00:00 CEST | Press release
With the recent update of its Document Reader SDK, Regula became the first identity verification (IDV) vendor to make it possible to verify all the dynamic security features of documents in real time. With the latest addition of Dynaprint® checks, the solution ensures more robust physical document authentication during remote onboarding. The innovation has arrived at a time when 58% of businesses globally face fake or modified IDs during digital onboarding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422724077/en/ Dynaprint in the Arizona’s driver’s license (Photo: Regula) Dynaprint® is a dynamic security feature consisting of two different images printed with lenticular technology. Depending on the angle of observation, only one image is visible at a time. Like all other dynamic security features, Dynaprint is crucial for securing identity documents from tampering, since it’s a tricky task to fake it without special e
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression22.4.2025 12:00:00 CEST | Press release
Highlights: Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on track to disclose top-line 6-week primary endpoint results in late June. “Completing dosing of all participants in Part A of our 005 trial marks a critical milestone in our mission to address the pressing unmet need in treatment resistant depression,” said Kabir Nath, CEO Compass Pathways. “We are proud of this achievement which reflects our team’s commitment to scient
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom